HRAS and neoplasm: By comparison, Erastin has been reported to exhibit greater lethality in human tumor cells harboring mutations in the oncogenes HRAS, KRAS, or BRAF (17) as well as in an individual genetic context using isogenic cell lines with and without oncogenic RAS genes (10).